Saroglitazar Magnesium is a novel agonist of peroxisome proliferator-activated receptor (PPAR)(predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively).

In db/db mice, Saroglitazar (0.01-3 mg/kg per day, orally) treatment with 12-day causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose.in Wistar rats and marmosets A 90-day repeated dose comparative study confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes.

1639792-20-3

C50H56MgN2O8S2

901.42

Saroglitazar Magnesium

DMSO:50 mg/mL (55.47 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years